300199.SZ
翰宇药业
SZSE · Healthcare · C 制造业 · CN
CNY 22.17
−4.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 955.5M | 966.4M | 590.2M | 431.4M | 704.3M |
| Cost of Revenue | 379.3M | 402.4M | 253.2M | 218.7M | 159.6M |
| Gross Profit | 576.2M | 564.0M | 337.0M | 212.7M | 544.7M |
| Operating Expenses | |||||
| R&D Expense | 136.0M | 126.9M | 88.0M | 161.5M | 158.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 127.7M | 124.0M | 122.4M | 127.7M | 106.5M |
| Selling & Marketing Expense | 93.1M | 107.0M | 119.5M | 242.6M | 375.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 484.9M | 484.1M | 454.8M | 669.8M | 765.0M |
| Cost and Expenses | 864.2M | 886.5M | 708.0M | 888.4M | 924.7M |
| Operating Income (EBIT) | 130.0M | 69.1M | (161.4M) | (507.5M) | (370.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 124.8M | 64.2M | (162.4M) | (511.1M) | (372.8M) |
| Income Tax Expense | 32.8M | 30.2M | 17.7M | 4.3M | (265.0K) |
| Bottom Line | |||||
| Net Income | 94.5M | 36.6M | (173.7M) | (513.9M) | (370.6M) |
| Earnings from Cont. Ops | 92.0M | 34.0M | (180.1M) | (515.4M) | (372.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 94.5M | 36.6M | (173.7M) | (513.9M) | (370.6M) |
| Per Share | |||||
| Basic EPS | CN¥0.10 | CN¥0.04 | (CN¥0.20) | (CN¥0.58) | (CN¥0.42) |
| Diluted EPS | CN¥0.10 | CN¥0.04 | (CN¥0.20) | (CN¥0.58) | (CN¥0.42) |
| Revenue Per Share | CN¥1.05 | CN¥1.06 | CN¥0.68 | CN¥0.49 | CN¥0.80 |
| Shares | |||||
| Basic Shares Outstanding | 913.0M | 914.2M | 868.3M | 886.0M | 882.3M |
| Diluted Shares Outstanding | 913.0M | 914.2M | 868.3M | 886.0M | 882.3M |
| Profitability Metrics | |||||
| EBITDA | — | 207.3M | (11.3M) | (353.8M) | (237.4M) |
| D&A | — | 138.2M | 150.1M | 153.7M | 133.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026